PLX — Protalix Biotherapeutics Balance Sheet
0.000.00%
- $118.61m
- $99.16m
- $53.40m
- 39
- 46
- 60
- 46
Annual balance sheet for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 18.3 | 39 | 17.1 | 23.6 | 19.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2 | 3.44 | 4.59 | 5.27 | 2.91 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 55.7 | 61.7 | 44.9 | 69.9 | 60.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.4 | 9.92 | 9.64 | 10.9 | 10 |
Other Long Term Assets | |||||
Total Assets | 67.9 | 73.7 | 55.8 | 84.4 | 73.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 86.5 | 33.2 | 32.4 | 45.5 | 25.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 95 | 79.7 | 66.4 | 50.9 | 30.2 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -27 | -6.04 | -10.6 | 33.6 | 43.2 |
Total Liabilities & Shareholders' Equity | 67.9 | 73.7 | 55.8 | 84.4 | 73.4 |
Total Common Shares Outstanding |